cGMP合规药品包装企业评估:产品完整性与全球供应所需能力
cGMP-Compliant Pharmaceutical Packaging Companies: Capabilities to Evaluate for Product Integrity and Global Supply
选择cGMP合规的药品包装企业需审查其合规体系与防护设计,全球采购覆盖、安全特性和对患者结局的影响与价格和速度同等重要。单次受损运输即可抵消多年制剂工作,引发监管扣留或危及全球供应链中的患者安全。
News|Articles|November 11, 2026
A single compromised shipment can undo years of formulation work, trigger a regulatory hold or put patient safety at risk across the global supply chain. Selecting a current Good Manufacturing Practice (cGMP) compliant pharmaceutical packaging company means scrutinizing its compliance systems and protective design. Global sourcing reach, security features and impact on patient outcomes matter just as much as price and speed.
Related to this article
November 11th, 2026
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
November 11th, 2026
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
November 11th, 2026
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
November 11th, 2026
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
November 11th, 2026
Beam’s base-edited cell therapy met its primary endpoint in the BEACON trial, and a U.S. biologics license application is planned as early as year-end.
November 11th, 2026
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
November 10th, 2026
AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.
November 10th, 2026
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
来源:BioPharm International · biopharminternational.com






